Published in PLoS Pathog on August 21, 2014
Emerging roles for RNA degradation in viral replication and antiviral defense. Virology (2015) 1.08
Viral inhibition of the transporter associated with antigen processing (TAP): a striking example of functional convergent evolution. PLoS Pathog (2015) 0.98
Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma. Exp Mol Med (2015) 0.89
The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-II. J Virol (2015) 0.78
Immune control of oncogenic γ-herpesviruses. Curr Opin Virol (2015) 0.76
The Epstein-Barr Virus Glycoprotein gp150 Forms an Immune-Evasive Glycan Shield at the Surface of Infected Cells. PLoS Pathog (2016) 0.75
HLA Allele E*01:01 Is Associated with a Reduced Risk of EBV-Related Classical Hodgkin Lymphoma Independently of HLA-A*01/*02. PLoS One (2015) 0.75
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med (2006) 4.42
Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol (2007) 4.14
Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet (1998) 3.94
The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J (2000) 3.52
The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity (1997) 2.93
Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol (1992) 2.83
Pathways of antigen processing. Annu Rev Immunol (2013) 2.82
Post-transplant lymphoproliferative disorders. Annu Rev Med (2005) 2.82
Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J Virol (1991) 2.58
Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A (1998) 2.46
A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity (1997) 2.45
Human herpes simplex virus (HSV)-specific CD8+ CTL clones recognize HSV-2-infected fibroblasts after treatment with IFN-gamma or when virion host shutoff functions are disabled. J Immunol (1996) 1.88
The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog (2009) 1.86
Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc Natl Acad Sci U S A (2007) 1.82
Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets. Blood (2010) 1.75
A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med (2007) 1.70
CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J Exp Med (2005) 1.61
Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis (2005) 1.52
CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J Virol (2005) 1.49
Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects. J Infect Dis (2004) 1.38
The switch from latent to productive infection in epstein-barr virus-infected B cells is associated with sensitization to NK cell killing. J Virol (2006) 1.35
The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog (2009) 1.31
The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules. J Virol (2002) 1.29
The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+ T cells through an additional host shutoff function. J Virol (2007) 1.29
Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc Natl Acad Sci U S A (2006) 1.26
Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection. J Immunol (2005) 1.23
Kinetics of antigen expression and epitope presentation during virus infection. PLoS Pathog (2013) 1.21
Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol (2004) 1.20
Viral interference with antigen presentation does not alter acute or chronic CD8 T cell immunodominance in murine cytomegalovirus infection. J Immunol (2007) 1.20
Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation. J Immunol (2009) 1.17
Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology. Semin Cancer Biol (2009) 1.16
A bridge crosses the active-site canyon of the Epstein-Barr virus nuclease with DNase and RNase activities. J Mol Biol (2009) 1.15
Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle. PLoS Pathog (2009) 1.11
Epstein-Barr virus-encoded BILF1 is a constitutively active G protein-coupled receptor. J Virol (2005) 1.10
Cross-presentation of a spread-defective MCMV is sufficient to prime the majority of virus-specific CD8+ T cells. PLoS One (2010) 1.08
The Epstein-Barr virus alkaline exonuclease BGLF5 serves pleiotropic functions in virus replication. J Virol (2009) 1.01
The Epstein-Barr virus BILF1 gene encodes a G protein-coupled receptor that inhibits phosphorylation of RNA-dependent protein kinase. J Virol (2005) 1.00
Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood (2012) 1.00
Priming of CD8+ T cells against cytomegalovirus-encoded antigens is dominated by cross-presentation. J Immunol (2013) 0.96
Immune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity. Microbes Infect (2010) 0.94
T cell detection of a B-cell tropic virus infection: newly-synthesised versus mature viral proteins as antigen sources for CD4 and CD8 epitope display. PLoS Pathog (2009) 0.94
EBV BILF1 evolved to downregulate cell surface display of a wide range of HLA class I molecules through their cytoplasmic tail. J Immunol (2013) 0.93
Truncated form of the Epstein-Barr virus protein EBNA-LP protects against caspase-dependent apoptosis by inhibiting protein phosphatase 2A. J Virol (2007) 0.92
EBV protein BNLF2a exploits host tail-anchored protein integration machinery to inhibit TAP. J Immunol (2011) 0.91
CD8+ T cell responses to lytic EBV infection: late antigen specificities as subdominant components of the total response. J Immunol (2013) 0.84
Innate immune responses against Epstein Barr virus infection. J Leukoc Biol (2013) 0.84
Varicella zoster virus (VZV) and herpes simplex virus (HSV) in solid organ transplant patients. Am J Transplant (2013) 0.80
Detection of EBV latent proteins by western blotting. Methods Mol Biol (2001) 0.80